Quantedge Capital’s Haemonetics HAE Stock Holding History

Quantedge Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,700	Closed	-$223K	–	144
2023 Q1	$223K	Buy	+2,700	New	+$219K	0.09%	121

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quantedge Capital's HAE Position: Q2 2023 in Review

Quantedge Capital sold out of Haemonetics (HAE) in Q2 2023, closing a stake of 2,700 shares — an estimated $223K sold.

Quantedge Capital first reported a position in HAE in Q1 2023 and held it in 1 quarter. The position peaked at $223K in Q1 2023. 296 funds tracked by Wall St. Rank hold HAE as of Q2 2023.

Quantedge Capital reported no remaining Haemonetics position as of Q2 2023 after selling out during the quarter.
Quantedge Capital sold 2,700 Haemonetics shares in Q2 2023, an estimated $223K.
Quantedge Capital first reported a position in Haemonetics in Q1 2023 and held it in 1 quarter.
Quantedge Capital's Haemonetics position peaked at $223K in Q1 2023.
296 funds tracked by Wall St. Rank held Haemonetics as of Q2 2023.

Based on Quantedge Capital's 13F filing for Q2 2023, filed 11 Aug 2023.